The Pharma Data

JANUARY 22, 2021

iosBio , a UK-based biotechnology company, has announced an exclusive worldwide licensing agreement with ImmunityBio , a clinical-stage immunotherapy company, for rights to use iosBio’s OraPro vaccine platform technology to test the oral administration of ImmunityBio’s vaccine candidate.

Vaccine 52

Vaccine Immune Response Government RNA 52

The Pharma Data

OCTOBER 14, 2020

The research is part of an ongoing collaboration between Columbia University and Tonix that focuses on T cell and antibody responses to SARS-CoV-2 (CoV-2), the virus that causes COVID-19. The research encompasses two projects. The study led by Dr. Ilya Trakht, Ph.D., About TNX-1800. 1 Noyce RS, et al. 2018) PLoS One. 13(1):e0188453.

Vaccine 40

Vaccine Pharmaceuticals Small Molecule Virus 40

The Pharma Data

NOVEMBER 22, 2020

MP0420 is subject to an option and license agreement with Novartis AG to develop, manufacture and commercialize Molecular Partners’ anti-COVID-19 DARPin® program. The DARPin® platform is a fast and cost-effective drug discovery engine, producing drug candidates with optimized properties for development and very high production yields.

Trials 40

Trials Clinical Trials Licensing Licensing 40

Codon

FEBRUARY 13, 2024

doi: 10.2210/rcsb_pdb/goodsell-gallery-048 The Virus that Cures It’s been over 25 years since the science magazine Discover first ran an extraordinary article about how a long-forgotten medical treatment, used in the former Soviet country of Georgia, could save us from the growing threat of untreatable, drug-resistant infections.

Therapies 136

Therapies Virus DNA Clinical Trials 136

The Pharma Data

JUNE 2, 2022

Boehringer Ingelheim and the Agency for Science, Technology and Research (A*STAR) today announced a global licensing agreement under which Boehringer Ingelheim will obtain exclusive worldwide rights to research, develop and commercialize products based on a panel of innovative, tumor-specific antibodies from A*STAR. star.edu.sg.

Licensing 52

Licensing Licensing Therapies Science 52

The Pharma Data

JANUARY 11, 2021

a San Diego-based biotechnology company with an array of technology platforms for antibody discovery and optimization, and novel NK and T cell engager generation, today announced licensing of a panel of its anti-SARS-CoV-2 antibody clones to IGM Biosciences for COVID-19 therapy development.

Licensing 52

Licensing Licensing Therapies Engineering 52

Codon

APRIL 2, 2023

This is Codon Digest, a weekly roundup of research papers, news articles, and industry highlights about engineered biology. Read Biological Engineering mScarlet3: a brilliant and fast-maturing red fluorescent protein. CRISPRi-mediated tunable control of gene expression level with engineered single-guide RNA in Escherichia coli.

DNA 52

DNA RNA Engineering Licensing 52

The Pharma Data

JULY 3, 2025

For years, the company was primarily known for licensing its C1 platform for the development of therapeutic biologics and vaccines. Our C1 and Dapibus™ production platforms remain the engines we expect to drive commercial execution. The rebranding reflects our top priority: to deliver high-value input proteins at commercial scale.”

International 52

International Licensing Licensing Protein Production 52

The Pharma Data

APRIL 18, 2022

Novavax licensed and transferred its manufacturing technologies to enable Takeda to develop and manufacture the vaccine at its facility in Hikari. Additional therapeutics: The company has assessed existing Takeda products for activity against the COVID-19 virus and co-founded the COVID R&D Alliance.

Vaccine 52

Vaccine Clinical Trials Trials Virus 52

The Pharma Data

OCTOBER 27, 2020

Novartis has been granted an option to in-license global rights of MP0420 and MP0423 – multi-targeted direct-acting antiviral therapeutic candidates demonstrating potential efficacy against COVID-19. These building blocks are designed to target different sites on the virus for multiple concurrent effects.

Therapies 40

Therapies Virus Treatment Clinical Trials 40

The Pharma Data

JULY 29, 2021

Takeda has granted a license to HilleVax for the exclusive development and commercialization rights to its norovirus vaccine candidate, HIL-214 (formerly TAK-214), worldwide outside of Japan, in exchange for upfront consideration, as well as future cash milestones and royalties on net sales. About HilleVax.

Vaccine 52

Vaccine Pharmaceutical Companies Clinical Trials Virus 52

The Pharma Data

DECEMBER 20, 2020

BT-001 is a best-in-class oncolytic Vaccinia virus. platform and its patented large-capacity VV cop TK-RR- oncolytic virus, which has been engineered to encode both a Treg-depleting human recombinant anti-CTLA4 antibody generated by BioInvent’s proprietary n-CoDeR ® /F.I.R.S.T LUND, Sweden and STRASBOURG, France , Dec.

Virus 40

Virus Trials Clinical Trials Clinical Development 40

Codon

MAY 2, 2023

To use it, mosquitoes are bred in exactly the same way that I’ve already described, but with one major difference: Instead of infecting females with a bacterium, they are genetically engineered to express the Cas9 protein (one part of the CRISPR system ), while male mosquitoes are engineered to express guide RNAs.

Engineering 52

Engineering Packaging Licensing Licensing 52

Codon

MAY 2, 2023

To use it, mosquitoes are bred in exactly the same way that I’ve already described, but with one major difference: Instead of infecting females with a bacterium, they are genetically engineered to express the Cas9 protein (one part of the CRISPR system ), while male mosquitoes are engineered to express guide RNAs.

Engineering 52

Engineering Packaging Licensing Licensing 52

Codon

JULY 27, 2023

But for a recent paper out of Nanjing, China, researchers engineered another enzyme and showed that, when mixed with FAST-PETase, the two worked together to break down plastic twice as fast as the Texas enzyme alone. Another paper recently reported an engineered Cas protein that is “up to 11.3-fold No longer.

Therapies 52

Therapies RNA DNA Engineering 52

Codon

JULY 27, 2023

But for a recent paper out of Nanjing, China, researchers engineered another enzyme and showed that, when mixed with FAST-PETase, the two worked together to break down plastic twice as fast as the Texas enzyme alone. Another paper recently reported an engineered Cas protein that is “up to 11.3-fold No longer.

Therapies 52

Therapies RNA DNA Engineering 52

The Pharma Data

MARCH 16, 2021

Pascal Soriot, Chief Executive Officer, said: “The long-acting antibody combination has the potential to offer almost immediate protection to those who are not able to be vaccinated, to both prevent infection or treat the disease in patients already infected with the virus. Financial considerations. Source link:[link].

Treatment 52

Treatment Virus Trials Government 52

Codon

SEPTEMBER 29, 2024

At best, the corporations with the best models released weak versions to the public under non-commercial licenses. On the surface, they hadn't deviated much from the early 2020s: a virus infected a cell and released the genetic therapy hidden within. The pessimism of just a few years before was replaced with exuberant optimism.

Engineering 144

Engineering Virus DNA Therapies 144

The Pharma Data

OCTOBER 15, 2020

The award honors McHutchison’s work in developing life-changing and curative therapies for patients with the hepatitis C virus. Additionally, Sarah Haecker Meeks, joined the Company as vice president of Business Development and Steve Nardi joined as vice president of Manufacturing and Engineering Operations.

Pharmaceuticals 52

Pharmaceuticals Clinical Pharmacology Medical Schools Vaccine 52

The Pharma Data

JANUARY 13, 2021

TNX-1500 is a third generation anti-CD40-ligand mAb that has been designed by protein engineering to decrease Fc?RII Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing small molecules and biologics to treat and prevent human disease and alleviate suffering.

Pharmaceuticals 52

Pharmaceuticals Small Molecule Vaccine Protein Expression 52

The Pharma Data

SEPTEMBER 15, 2020

With the depth and breadth of our current portfolio, the tremendous potential of our pipeline and scientific engine, and the power of our culture of innovation, we are poised to continue delivering meaningful value to patients by addressing some of the world’s most difficult health challenges.”. BNT162 mRNA-based Vaccine Program.

Vaccine 52

Vaccine Therapies Trials Clinical Trials 52

Agency IQ

NOVEMBER 3, 2023

None of the products discussed thus far should be confused with “synthetic biotics” “Synthetic biotics,” also referred to as engineered living therapeutics , are bacteria that have been genetically altered to perform a specific function for diagnostic or therapeutic benefit. Thus, they could also technically be considered synthetic biotics.

Therapies 40

Therapies Science FDA Production 40

Drug Target Review

JULY 19, 2023

Thanks to recent breakthroughs 3 in cell engineering and photosynthetic biomanufacturing, it is now possible to cost-effectively manufacture, at large scale, mucosally delivered biologics. Seven years ago, Lumen scientists discovered methods for genetic engineering of spirulina and production of exogenous proteins, such as vaccine antigens.

Vaccine 96

Vaccine Disease Engineering Virus 96

PLOS: DNA Science

SEPTEMBER 7, 2023

Now, college tuition includes a fee to license an e-textbook for a limited time. A French major wanting to become an engineer would have to start over, taking very different courses. Tomes were split into shorter versions, like calving icebergs. The first E-books date from the 1990s. ” That definition covers all bases.

DNA 98

DNA Science Therapies Licensing 98

The Pharma Data

JANUARY 24, 2021

Transgene and BioInvent received approval from France’s national regulatory agency to begin a Phase I/IIa trial of Vaccinia virus BT-001 in solid tumors. oncolytic virus (VVcopTK-RR-) and engineered to encode both a Treg-depleting human recombinant anti-CTLA4 antibody and the human GM-CSF cytokine.

Long-Term Care Facilities 52

Long-Term Care Facilities Trials Virus Clinical Trials 52

Codon

MAY 18, 2023

And the article doesn’t mention how Pairwise engineered the mustard to be “less pungent.” The company also has licensing deals with Tropic Biosciences to make bananas that don't brown as fast and coffee with naturally low caffeine & high solubility (for instant coffee). Maybe for real this time? in a series A.

DNA 52

DNA Therapies Engineering Virus 52

Codon

MAY 18, 2023

And the article doesn’t mention how Pairwise engineered the mustard to be “less pungent.” The company also has licensing deals with Tropic Biosciences to make bananas that don't brown as fast and coffee with naturally low caffeine & high solubility (for instant coffee). Maybe for real this time? in a series A.

DNA 52

DNA Therapies Engineering Virus 52

Codon

APRIL 16, 2023

Codon Digest is my weekly roundup of research, news, and industry highlights about engineered biology. These microbes were engineered to express tumor antigens that could “elicit T cells that were licensed by the commensal immune program but specific for a tumor,” including both CD4+ and CD8+ T cells, according to the study.

Engineering 52

Engineering DNA RNA Science 52

The Pharma Data

APRIL 1, 2021

Kite, a Gilead Company (Nasdaq: GILD), today announced that it has submitted a supplemental Biologics License Application (sBLA) to the U.S. Hepatitis B virus (HBV) reactivation, in some cases resulting in fulminant hepatitis, hepatic failure, and death, can occur in patients treated with drugs directed against B cells.

Virus 52

Virus Treatment Therapies FDA 52

Codon

MAY 11, 2023

Scroll to the end for a beautiful chart about the Anthropocene & some details on insect engineering companies. It is used to prevent respiratory syncytial virus, or RSV, which causes about 60,000 hospitalizations in this age group each year. There are many other up-and-coming insect engineering startups. Let’s dive in.

Vaccine 52

Vaccine Engineering Licensing Licensing 52

Codon

MAY 11, 2023

Scroll to the end for a beautiful chart about the Anthropocene & some details on insect engineering companies. It is used to prevent respiratory syncytial virus, or RSV, which causes about 60,000 hospitalizations in this age group each year. There are many other up-and-coming insect engineering startups. Let’s dive in.

Vaccine 52

Vaccine Engineering Licensing Licensing 52

DrugBaron

NOVEMBER 9, 2020

And yet, with interim data announced today showing a vaccine candidate from Pfizer and BioNTech to have at least 90% efficacy, it seems certain a vaccine to protect against a virus that was unknown to science a year ago will be approved in the US and Europe, before the end of 2020.

Vaccine 100

Vaccine Pharmaceutical Companies Government Pharmaceuticals 100

Drug Target Review

APRIL 11, 2025

During the COVID-19 pandemic, BenevolentAI used its AI platform to identify baricitinib as a potential treatment for the virus in just three days, an impressive example of rapid repurposing of existing drugs. Recently Recursion Pharmaceuticals unbiased, machine learning-powered genomics screen rapidly identified and advanced REC-1245.

Clinical Development 97

Clinical Development Drugs Pharmaceuticals Clinical Trials 97

The Pharma Data

MARCH 26, 2021

Data from the registrational COMET-ICE trial also will form the basis for a Biologics License Application (BLA) submission to the FDA. Importantly, VIR-7832 also has been engineered to potentially enhance virus-specific T cell function, which could help treat and/or prevent COVID-19 infection.

Treatment 52

Treatment FDA Vaccine Trials 52

The Pharma Data

SEPTEMBER 8, 2020

is undergoing clinical trials for NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19. (Nasdaq:NVAX) is a late-stage biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases.

Science 52

Science Vaccine Clinical Trials Pharmaceutical Companies 52

The Pharma Data

SEPTEMBER 8, 2020

Novavax is undergoing clinical trials for NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19. (Nasdaq:NVAX) is a late-stage biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases.

Science 52

Science Vaccine Clinical Trials Pharmaceutical Companies 52

Drug Target Review

APRIL 9, 2025

Now, his focus is on Gylden Pharma’s nanoparticle-based vaccine platform – a cutting-edge solution that bypasses the limitations of traditional RNA and live attenuated virus vaccines. T cells in the bloodstream are of no use – you need them in the tissues, waiting for the virus to arrive.

Virus 95

Virus Vaccine RNA Trials 95